Sage advice: psychiatric drug development is tough
As a phase III blow-up brings Sage Therapeutics’ run of success to an end, the company’s post-hoc analyses fail to reassure investors that its depression project has a…
Upcoming events – Sage targets depression and Biogen aims for lupus
Sage's big depression readout looms, while Biogen hopes for a mid-stage hit in lupus.
Does amount matter when it comes to a biotech IPO?
Biontech and ADC Therapeutics are both heading towards substantial flotations, but it is hard to find evidence that bigger does better.
Marinus leaves the way clear for Sage
In the wake of a clinical trial failure Marinus plays down oral ganaxolone, but investors are unimpressed.
Array-size deals don’t come around too often
Pfizer’s Array buyout ranks as 2019’s second largest, but the price sits in a lonely space in the deal universe.
Splitting the difference on promising pipeline asset predictions
An analysis looking at forecast discrepancies for the top pipeline projects reveals vast differences of opinion about Vertex's cystic fibrosis triplet and Novo…
No, aducanumab is not an Alzheimer’s drug either
Failure at a futility analysis blows a big hole in Biogen's pipeline. Can the company buy in growth or will its valuation sink enough for it to become a target?
